Cargando…
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
Claudin 18.2 (CLDN18.2) is a tight-junction protein. CLDN18.2-targeting strategy has cut a striking figure in CLDN18.2 positive patients with advanced gastric cancer. Zolbetuximab, the CLDN18.2 antibody, obtained a better clinical benefit in patients compared with the controlled. In phase II trials,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219097/ https://www.ncbi.nlm.nih.gov/pubmed/32410803 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.13 |